FATE - Fate Therapeutics, Inc. News

Sectors

FATE

Fate Therapeutics, Inc.

2.52

2 x 1.91

2 x 3.28

bid

ask

0.01

0.59%

10:06 AM

timesize

Ytd	156.63%
1y	161.98%

2.44

day range

2.52

0.94

52 week range

3.23

Open	2.52	Prev Close	2.53	Low	2.44	High	2.52	Mkt Cap	301.35M
Vol	252.76K	Avg Vol	2.75M	EPS	-1.05	P/E	N/A	Forward P/E	-0.99
Beta	2.54	Short Ratio	3.10	Inst. Own	102.25%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	11-12	50-d Avg	2.56	200-d Avg	1.79	1yr Est	6.31

FATE News

benzinga.com

Fate Therapeutics Says Four Abstracts From Off-The-Shelf CAR T-Cell Programs Selected For Presentati

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

globenewswire.com

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfoli

SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-sta

benzinga.com

Fate Therapeutics To Present Clinical Data From Off-The-Shelf Anti-CD19 CAR T-Cell Product Candidate

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

globenewswire.com

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Prod

SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-sta

globenewswire.com

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Confer

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-sta

defenseworld.net

BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE

BlackRock Inc. acquired a new position in shares of Fate Therapeutics, Inc. (NASDAQ: FATE) in the un

seekingalpha.com

Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead

Fate Therapeutics has initiated the phase 2 RECLAIM-LN trial of FT819 in lupus nephritis, dosing the

benzinga.com

Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweigh

benzinga.com

Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and r

benzinga.com

Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and main

benzinga.com

Fate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Pot

First patient dosed in an outpatient setting, discharged the same day; multiple patients in the proc

globenewswire.com

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Tr

First patient dosed in an outpatient setting, discharged the same day; multiple patients in the proc

zacks.com

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensu

benzinga.com

Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analys

globenewswire.com

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utiliz

youtube.com

FATE UNKNOWN: If CLARITY DIES Democrats KILLED IT, Lummis says

Sen. Cynthia Lummis, R-Wyo., discusses the expected CLARITY Act vote, the budget agenda before reces

globenewswire.com

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

benzinga.com

Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Sess

US stock futures mostly higher, Nasdaq up by 100 points. Phoenix Education falls after cutting sales

benzinga.com

CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application F

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

globenewswire.com

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product C

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Mul

benzinga.com

Fate Therapeutics To Demonstrate Data On Its CAR T-cell Product Candidate FT819 At International Soc

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

globenewswire.com

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Can

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

globenewswire.com

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) --  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-sta

seekingalpha.com

Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive

Fate Therapeutics is a bet on their off-the-shelf cell therapies, which are now mostly centered on F

globenewswire.com

Fate Therapeutics Appoints Laura Hamill to Board of Directors

SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

benzinga.com

HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Fate Therapeutics (NASDAQ:FATE) with a Bu

benzinga.com

Fate Therapeutics Showcases Data Featuring Its CAR T-Cell Programs At European Congress Of Rheumatol

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to brin

globenewswire.com

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatol

FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21

globenewswire.com

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

globenewswire.com

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annua

FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemothera

benzinga.com

Fate Therapeutics To Feature Data From Off-The-Shelf CAR T-Cell Programs At 2026 ASCO And EULAR Annu

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

benzinga.com

Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analys

benzinga.com

Fate Therapeutics To Present Data For Its Off-The-Shelf CAR T-Cell Programs At American Society Of G

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

benzinga.com

10 Health Care Stocks Whale Activity In Today's Session

benzinga.com

Fate Therapeutics' FT819 Selected By FDA As Participant In Chemistry, Manufacturing And Controls Dev

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

benzinga.com

Fate Therapeutics Announces That Data From Its Off-The-Shelf CAR T-Cell Programs FT819, FT839 And FT

Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus

benzinga.com

HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy

benzinga.com

Fate Therapeutics To Present Clinical Data From Its FT819 Candidate At Congress Of Clinical Rheumato

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to brin

benzinga.com

Fate Therapeutics Says Preclinical Data From Next-Gen, Off-The-Shelf CAR T-Cell Product Candidate, F

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

benzinga.com

Fate Therapeutics Q4 Earnings Summary & Key Takeaways

benzinga.com

Earnings Summary: Fate Therapeutics Q4

benzinga.com

Fate Therapeutics Q4 EPS $(0.27) Misses $(0.26) Estimate, Sales $1.369M Beat $1.186M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which missed the anal

benzinga.com

Fate Therapeutics Presents Updated Clinical Data From Its Ongoing Phase 1 Trial Evaluating Its Ft819

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twel

benzinga.com

Fate Therapeutics Q3 EPS $(0.27) Beats $(0.29) Estimate, Sales $1.741M Beat $1.535M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which beat the analys

benzinga.com

HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5

HC Wainwright & Co. analyst Robert Burns upgrades Fate Therapeutics (NASDAQ:FATE) from Neutra

benzinga.com

Wedbush Upgrades Fate Therapeutics to Outperform, Raises Price Target to $7

Wedbush analyst David Nierengarten upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Outpe

benzinga.com

Reported Sunday, Fate Therapeutics Presents FT819 Phase 1 Data Demonstrating Immune Remodeling And D

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-sev

benzinga.com

12 Health Care Stocks Moving In Tuesday's Intraday Session

benzinga.com

Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wedne

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.

benzinga.com

Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mi